Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context

Summary: Background: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1–4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angioge...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2024-05-01
Cyfres:	EClinicalMedicine
Pynciau:	Anlotinib Anti-tumor angiogenesis Triple-negative breast cancer Neoadjuvant chemotherapy
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2589537024001640
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!